2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
38
Colorectal Neoplasms
18
Small Cell Lung Carcinoma
8
Neoplasms
8
Stomach Neoplasms
7
Neoplasm Metastasis
5
Biliary Tract Neoplasms
5
Sarcoma, Ewing
4
Rhabdomyosarcoma
4
Recurrence
4
Osteosarcoma
4
Rectal Neoplasms
3
Ovarian Neoplasms
3
Cholangiocarcinoma
3
Triple Negative Breast Neoplasms
2
Solid Tumor
2
Neuroblastoma
2
Nasopharyngeal Carcinoma
2
Metastatic Pancreatic Adenocarcinoma
2
Head and Neck Neoplasms
2
Glioma
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Wilms Tumor
1
Weight Loss
1
Somatostatinoma
1
Solid Tumor Cancer
1
Small Cell Lung Cancer Extensive Stage
1
Interventions
Gemcitabine
40
Cisplatin
24
Capecitabine
21
Fluorouracil
19
Oxaliplatin
17
Leucovorin
14
pembrolizumab
9
Irinotecan
8
Radiotherapy
7
Erlotinib Hydrochloride
7
durvalumab
6
Sorafenib
4
Photochemotherapy
4
Magnetic Resonance Spectroscopy
4
Carboplatin
4
trametinib
3
Trastuzumab
3
Radiofrequency Ablation
3
Long-Term Synaptic Depression
3
Interleukin-12 Subunit p35
3
Filgrastim
3
Drug Therapy
3
Dihematoporphyrin Ether
3
Dexamethasone
3
Cholangiopancreatography, Endoscopic Retrograde
3
Chemotherapy, Adjuvant
3
trifluridine tipiracil drug combination
2
tivozanib
2
tislelizumab
2
spartalizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Bile Duct Neoplasms
×
irinotecan sucrosofate
×
Clear all
NCT05277766
2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1
Recruiting
45 enrolled